Article info
PDFClinical and epidemiological research
Extended report
Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study
- Correspondence to Professor Josef S Smolen, Division of Rheumatology, Medical University of Vienna and Department of Medicine III, Hietzing Hospital, Waehringer Guertel 18-20, Vienna A-1090, Austria; josef.smolen{at}wienkav.at
Citation
Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study
Publication history
- Received February 7, 2013
- Revised May 14, 2013
- Accepted June 29, 2013
- First published July 29, 2013.
Online issue publication
September 04, 2014
Article Versions
- Previous version (29 July 2013).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/